医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Opportunities and Challenges in China Will Be Topic of Theorem Clinical Research Presentation at Partnerships in Clinical Trials Conference

2012年10月31日 PM09:25
このエントリーをはてなブックマークに追加


 

KING OF PRUSSIA, Pa.

Overcoming the challenges of conducting China’s largest outcomes trial and how it relates to doing business in this vital emerging market will be the topic of a joint presentation by Anja Moellman, Senior Project Director for Theorem Clinical Research, and Zoe Doran, Head of Clinical Research for the Diabetes Trials Unit at the University of Oxford Centre for Diabetes, Endocrinology and Metabolism.

“What are the Real Opportunities and Challenges in China?” is scheduled as a November 8 session of the 11th annual Partnerships in Clinical Trials conference in Hamburg, Germany, November 6-9.

Moellman and Doran have been involved in a six-year Acarbose Cardiovascular Evaluation study in China and Hong Kong involving more than 7,500 patients and 165 investigative sites.

“Theorem stepped in after attempts by other CROs failed because of poor data quality and low patient recruitment as well as a variety of issues at individual investigative sites,” said Marc Hoffman, General Manager, Biopharmaceutical Development for Theorem. “Theorem’s aggressive plan for resolving problems and doubling the rate of patient randomization can serve as a valuable blueprint to anyone planning to do research in China.”

A true global Contract Research Organization (CRO), Theorem has been in Europe for more than 20 years and has been conducting clinical trials in China since 2003. The company has offices in Australia, Asia, the Middle East and throughout North and South America. Theorem will exhibit at the conference in booth #519.

About Theorem Clinical Research

Theorem Clinical Research Inc. is a leading midsized provider of comprehensive clinical research and development services with offices in more than 30 countries and a customer base comprised of some of the world’s leading pharmaceutical, biotech and medical device companies. A leader in medical device and drug-device combination trials in addition to a notable capability in pharmaceuticals and biologics, Theorem has deep expertise in a broad range of therapeutic areas and in all phases of development. Some of the industry’s top scientists and most advanced clinical analytics capabilities help ensure smooth-running, successful trials. For a full-service, right-size global research partner, don’t think twice. THINK THEOREM.

CONTACT

Theorem Clinical Research
Shawn Clary, 484-679-2400
shawn.clary@theoremclinical.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates